Basic Information
| LncRNA/CircRNA Name | FOXC2-AS1 |
| Synonyms | FOXC2-AS1, ODRUL |
| Region | GRCh38_16:86565145-86567761 |
| Ensemble | ENSG00000260944 |
| Refseq | NR_125795 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | prostate cancer |
| ICD-0-3 | C61.9 |
| Methods | qPCR, Western blot, Luciferase reporter assay, other |
| Sample | prostate cancer tissues and cell lines (LNCaP, DU145, VCaP, PC-3) |
| Expression Pattern | up-regulated |
| Function Description | Mechanically, we found that miR-1253 targeted FOXC2-AS1 at the 3'-untranslated regions (UTR), which in turn bind the EZH2 mRNA 3-UTR. Luciferase reporter assay and rescue experiment confirmed the FOXC2-AS1/miR-1253/EZH2 pathway. In conclusion, we confirmed that lncRNA FOXC2-AS1 accelerated the tumor progression of prostate cancer cells by regulating the proliferation and tumor growth through miR-1253/EZH2 axis. |
| Pubmed ID | 30389560 |
| Year | 2019 |
| Title | Long noncoding RNA FOXC2-AS1 facilitates the proliferation and progression of prostate cancer via targeting miR-1253/EZH2. |
External Links
| Links for FOXC2-AS1 | GenBank HGNC NONCODE |
| Links for prostate cancer | OMIM COSMIC |